| Biomarker ID | 254 |
| PMID | 18428198 |
| Year | 2008 |
| Biomarker | C-reactive protein (CRP) |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased in Overall Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.41 (95% CI: 1.199-1.647) |
| Effect on Pathways | Pathways Include:-Vitamin B12 metabolism,Selenium pathway, Folate metabolism,Interleukin-6 signaling pathway,Complement cascade |
| Experiment | Overall Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | 250 patients were considered for this placebo control study, out of which 160 blood plasma samples were used for analysis. (64%) |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.67 |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | sandwich immunoassay |
| Clinical | Yes |
| Remarks | Using Cox Regression Analysis. For AUC: ln CRP was accessed as a risk factor. |
| Clinical Trial Number | NCT00043576 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CRP |